+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in liposomal dry powder formulations: preparation and evaluation



Recent advances in liposomal dry powder formulations: preparation and evaluation



Expert Opinion on Drug Delivery 6(1): 71-89



Liposomal drug dry powder formulations have shown many promising features for pulmonary drug administration, such as selective localization of drug within the lung, controlled drug release, reduced local and systemic toxicities, propellant-free nature, patient compliance, high dose carrying capacity, stability and patent protection. Critical review of the recent developments will provide a balanced view on benefits of liposomal encapsulation while developing dry powder formulations and will help researchers to update themselves and focus their research in more relevant areas. In liposomal dry powder formulations (LDPF), drug encapsulated liposomes are homogenized, dispersed into the carrier and converted into dry powder form by using freeze drying, spray drying and spray freeze drying. Alternatively, LDPF can also be formulated by supercritical fluid technologies. On inhalation with a suitable inhalation device, drug encapsulated liposomes get rehydrated in the lung and release the drug over a period of time. The prepared LDPF are evaluated in vitro and in vivo for lung deposition behavior and drug disposition in the lung using a suitable inhaler device. The most commonly used liposomes are composed of lung surfactants and synthetic lipids. Delivery of anticancer agents for lung cancer, corticosteroids for asthma, immunosuppressants for avoiding lung transplantation rejection, antifungal drugs for lung fungal infections, antibiotics for local pulmonary infections and cystic fibrosis and opioid analgesics for pain management using liposome technology are a few examples. Many liposomal formulations have reached the stage of clinical trials for the treatment of pulmonary distress, cystic fibrosis, lung fungal infection and lung cancer. These formulations have given very promising results in both in vitro and in vivo studies. However, modifications to new therapies for respiratory diseases and systemic delivery will provide new challenges in conducting well-designed inhalation toxicology studies to support these products, especially for chronic diseases.

(PDF emailed within 0-6 h: $19.90)

Accession: 055398030

Download citation: RISBibTeXText

PMID: 19236209

DOI: 10.1517/17425240802652309


Related references

Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. International Journal of Pharmaceutics (Amsterdam) 190(1): 63-71, Nov 10, 1999

Design, Preparation and Evaluation of Liposomal Gel Formulations for Treatment of Acne: In vitro and In vivo Studies. Drug Development and Industrial Pharmacy: 1-40, 2018

Preparation of novel apigenin-enriched, liposomal and non-liposomal, antiinflammatory topical formulations as substitutes for corticosteroid therapy. PhytoTherapy Research 25(2): 228-233, 2011

Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects. Iranian Journal of Basic Medical Sciences 18(5): 506-513, 2015

Evaluation of several liposomal formulations and preparation techniques for the dermal delivery of phosphorothioate antisense oligonucleotides in hairless mouse skin. Pharmaceutical Research (New York) 12(9 SUPPL ): S269, 1995

Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine 25(37-38): 6818-6829, 2007

In vitro bactericidal evaluation of a low phase transition temperature liposomal tobramycin formulation as a dry powder preparation against gram negative and gram positive bacteria. Journal of Liposome Research 9(3): 301-312, 1999

Liposomal-polyene preliposomal powder and method for its preparation. Official Gazette of the United States Patent & Trademark Office Patents 1216(1): 489, Nov 3, 1998

Liposomal budesonide for dry powder inhaler: preparation and stabilization. Aaps Pharmscitech 2(4): 25-25, 2004

Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations. Drug Development and Industrial Pharmacy 37(11): 1376-1386, 2012

Preparation and characterization of liposomal formulations of tumor necrosis factor. Official Gazette of the United States Patent & Trademark Office Patents 1201(1): 361, Aug 5, 1997

Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods in Enzymology 391: 40-57, 2005

Liposomal formulations of protein proteinase inhibitors: preparation and specific activity. Biomeditsinskaia Khimiia 54(5): 561-569, 2009

Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors. International Journal of Pharmaceutics 416(2): 448-452, 2011

Preparation of dry reconstituted liposomal powder by freeze-drying at room temperature. Journal of Liposome Research 21(1): 28-37, 2011